How Clinicians Conceptualize “Actionability” in Genomic Screening
Journal of Personalized Medicine · 04.02.2023 · 13 (2) · 290
DOI: 10.3390/jpm13020290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 04.02.2023. Verfasst von Kellie Owens und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute.
Abstract (Originalsprache)
Over the last decade, the concept of actionability has become a primary framework for assessing whether genetic data is useful and appropriate to return to patients. Despite the popularity of this concept, there is little consensus about what should count as “actionable” information. This is particularly true in population genomic screening, where there is considerable disagreement about what counts as good evidence and which clinical actions are appropriate for which patients. The pathway from scientific evidence to clinical action is not straightforward—it is as much social and political as it is scientific. This research explores the social dynamics shaping the integration of “actionable” genomic data into primary care settings. Based on semi-structured interviews with 35 genetics experts and primary care providers, we find that clinicians vary in how they define and operationalize “actionable” information. There are two main sources of disagreement. First, clinicians differ on the levels and types of evidence required for a result to be actionable, such as when we can be confident that genomic data provides accurate information. Second, there are disagreements about the clinical actions that must be available so that patients can benefit from that information. By highlighting the underlying values and assumptions embedded in discussions of actionability for genomic screening, we provide an empirical basis for building more nuanced policies regarding the actionability of genomic data in terms of population screening in primary care settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, USA.
- Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Department of Anthropology, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Kellie Owens
Förderung
- NHGRI NIH HHS
- National Human Genome Research Institute
Zitieren
APA
Owens, K., Sankar, P., & Asfaha, D. M. (2023). How Clinicians Conceptualize “Actionability” in Genomic Screening. Journal of Personalized Medicine, 13(2), 290. https://doi.org/10.3390/jpm13020290
Vancouver
Owens K, Sankar P, Asfaha DM. How Clinicians Conceptualize “Actionability” in Genomic Screening. Journal of Personalized Medicine. 2023;13(2):290. doi:10.3390/jpm13020290
BibTeX
@article{Owens2023,
author = {Owens, Kellie and Sankar, Pamela and Asfaha, Dina M},
title = {How Clinicians Conceptualize “Actionability” in Genomic Screening},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {2},
pages = {290},
doi = {10.3390/jpm13020290}
}
EUVIMED